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To investigate soluble IL-2 receptor (sIL-2R) levels in na-
sal allergy, the sera and nasal secretions from patients
with nasal allergy and from healthy subjects were
subjected to a double-epitope enzyme-linked immuno-
sorbent assay. Significant elevation of sIL-2R concentra-
tions in the sera and nasal secretions was observed in the
allergy patients (n 26) compared with those of healthy
subjects (n 9). IL-2R-positive (CD25/) cells were ob-
served in the crust formed in an allergic nasal mucosa.
The concentration of sIL-2R in the sera correlated neither
with the eosinophil count of the peripheral blood count
nor with clinical severity. The concentration of sIL-2R in
the nasal secretions was significantly higher compared
with that in the sera from allergic patients (,O < 0.01),
whereas no significant difference was observed between
sIL-2R levels in the sera and nasal sections from normal
subjects. These findings indicate that sIL-2R plays an
essential role in allergic processes by regulating IL-2R-
positive cells recruited into the nasal mucosa.
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Introduction
Nasal allergy is a typical IgE-mediated allergic in-
flammation of the nasal mucosa where recruitment of
eosinophils, lymphocytes and mast cells, is observed.
Recent studies have elucidated the role of mast cells
and eosinophils in nasal allergy. However, the role
of lymphocytes in this condition remains to be deter-
mined despite advances in immunological studies of
cytokines and their receptors. Studies on the role of
lymphocytes in nasal allergy is thus crucial for eluci-
dation of the mechanism of allergic inflammation in
the nose, since lymphocyte activation following sig-
nalling by antigen-presenting cells may initiate sub-
sequent sequential immunological events.
Soluble IL-2 receptor (sIL-2R) is an
extracytoplasmic component of the chain subunit
shed from the IL-2 receptor. Recently, the elevation
of serum slL-2R level has been reported in some
diseases, including bronchial asthma. However, few
studies have been performed on slL-2R level in nasal
allergy. In the present study, slL-2R levels were de-
termined in the sera and nasal secretions obtained
from nasal allergy patients and from healthy control
subjects.
Materials and Methods
Subjects: Twenty-six patients were diagnosed as hav-
ing nasal allergy to house dust mite according to the
1995 Rapid Communications of Oxford Ltd
following criteria: (1) nasal symptoms, namely per-
sistent and recurrent nasal symptoms consisting of
sneezing attacks, watery nasal discharge and nasal
obstruction; (2) eosinophilia in nasal smear test; (3)
positive intradermal allergen reaction; and (4) posi-
tive serum IgE antibody which is specific for
dermatophagoides pteronyssinus, but not for pollens
from trees or grass, or fungus allergens. All patients
were free from other infectious and inflammatory
diseases for 4 weeks, and medications were discon-
tinued for 2 weeks before the allergological tests and
collection of nasal lavage fluids. Nine normal sub-
jects, age-.and sex-matched and negative in all these
allergy tests, volunteered to act as controls. The age
of the patients ranged from 21 to 32 years, and the
normal subjects ranged from 23 to 30 years in age.
Nasal symptom scores were assessed from a symp-
tom diary and evaluated to determine severity.
Preparationfor the measurement ofsIL-2R: Sera and
nasal lavage fluids were collected from 26 patients
with perennial nasal allergy and from nine normal
subjects. Peripheral blood was extracted and imme-
diately centrifuged twice at 1350 x g for 10 min at
4C, and the resultant sera were stored at-80C until
sIL-2R level was measured.
Nasal smears were obtained prior to nasal lavage
and investigated cytologically by Hansel’s staining
technique, and nasal cytograms were graded semi-
quantitatively.
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Nasal lavage was performed with 20 ml of 0.9%
saline solution with 1 mM LiC1 pre-warmed to 37C
using a plastic syringe, and the total volume of
recovered lavage fluid was measured. Suputolidin(R)
(Boehringer Diagnostics, La Jolla, CA, USA) was
mixed with nasal lavage fluid to homogenize at a
volume/concentration ratio of 0.4/9.0 and immedi-
ately vortexed for 1 min, after which 5.5% Aprotinin
(Sigma, MO, USA) was added at a volume/concentra-
tion ratio of 0.1/0.94, followed by immediate mixing
for 1 min at room temperature. The mixture was
allowed to stand for 30 min at room temperature,
then centrifuged at 1350 x g twice each time for
10 min at 4C, and the supernatant was stored at
-80C until slL-2R was assayed in duplicate. The
lithium (Li) concentration of the nasal lavage fluid
was measured by atomic emission spectro-
photometry to calculate sIL-2R concentration in the
nasal secretions. Li was used as an exogenous marker
of nasal secretion allowing measurement from small
amounts of nasal secretion. The slL-2R concentra-
tion of the nasal secretion (sIL-2Rx) was calculated
from the following equation: slL-2Rx sIL-2Rn x Lio/
(Lio-Lin), where slL-2Rn denotes the slL-2R concen-
tration of the sample; Lio, the Li concentration of the
lavage fluid containing 0.9% NaC1; and Lin, the Li
concentration of the sample.
Measurement of slL-2R by enzyme-linked
immunosorbent assay: The double-epitope enzyme-
linked immunosorbent assay was used for detecting
slL-2R in the sera and nasal lavage fluids (Cellfree
Interleukin-2 Receptor Bead Assay Kit(R), T-cell Sci-
ence, MA, USA). For the measurement of slL-2R in the
nasal lavage fluids, the effect of the lavage fluid itself
on the slL-2R assay was preliminarily tested and no
significant effect was found. Briefly, three nasal
lavage fluid sampleswere used for the test. An equal
volume of standard sIL-2R was added to each nasal
lavage fluid and the actual increase in slL-2R concen-
tration was compared with the calculated value. The
mean (+S.D.) actual increase was 95+4% of the cal-
culated value.
The assay was performed in duplicate. Briefly, 50
btl of standard or appropriately diluted serum was
added to 150 btl of the horseradish peroxidase-con-
jugated mouse anti-human slL-2R monoclonal anti-
body. One polystyrene bead coated with anti-human
slL-2R monoclonal antibody was incubated in the
above mixture for 90 min at room temperature on a
rotator set at 150 rpm. The bead was then washed
three times with 2 ml of deionized water each time.
Two hundred btl of the substrate (o-
phenylenediamine) was added to each tube and
incubated with the bead for 30 min at room tempera-
ture, and then 1 1 of H2SO was added to stop the
reaction. The solution was then decanted into a 96-
well fiat-bottomed plate for application to an auto-
matic spectrophotometer (Titerteck Multiscan(R) Plus
MKII, Flow Laboratories Inc., CA, USA). The absorb-
ance of the samples was measured with the
spectrophotometer after setting the zero using the
substrate blank. IL-2R concentration in the nasal
secretion was calculated according to the above
equation.
Immunocytochemical stainingforCD25 cells.. Speci-
mens of the inferior turbinate mucosa were fixed in
4% paraformaldehyde, embedded in OCT compound
and frozen at-80C. Fifteen m-thick sections were
cut, immersed in PBS containing 0.3% Triton-X, and
incubated in methyl alcohol containing 0.3% H202 for
20 min to inhibit endogenous tissue peroxidase ac-
tivity. After washing in PBS, the sections were further
incubated in normal goat serum for 30 min, washed
in PBS again, and then incubated overnight with
mouse monoclonal anti-human CD25 antibody
(Dako Ltd, High Wycombe, Buckinghamshire, UK),
at a dilution of 1:400. The sections were then washed
in PBS, and incubated with the biotinylated goat anti-
mouse IgG (the second antibody, Nichirei, Tokyo,
Japan) for 30 min, washed in PBS again, and incu-
bated with peroxidase-conjugated streptavidin for
30 min. The reaction was then developed by treat-
ment with diaminobenzidine for 10 min followed by
washing in PBS. The sections were subsequently
fixed in osmic acid solution and dehydrated before
mounting.
Statistics: The Kruskal-Wallis test was used to evalu-
ate the relationship between slL-2R values and clini-
cal severity. To evaluate the differences between the
values of the two groups, Wilcoxon rank-sum test
was used.
Results
Levels ofsIL-2R in the sera: The mean (+ S.D.) values
of serum slL-2R concentrations in the allergic patients
and of the normal subjects were 513 + 171 U/ml and
310 + 137 U/ml, respectively. In patients with nasal
allergy, the serum slL-2R concentration was signifi-
cantly higher as compared with that of the normal
subjects (p< 0.01, Fig. 1). However, there was no
significant correlation between serum slL-2R concen-
tration and clinical severity.
Levels ofslL-2R in nasal secretions: The mean (+ S.D.)
values of slL-2R concentrations in the nasal secre-
tions of the patients and of the normal subjects were
1 513 + 1 233 U/ml and 371 + 193 U/ml, respectively.
The concentration of slL-2R was significantly higher
in the nasal secretions of nasal allergy patients com-
pared with that of the normal subjects (p < 0.01).
However, there was no significant correlation be-
tween the concentrations of slL-2R in the nasal secre-
tions and clinical severity (Fig. 2). The slL-2R level
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FIG. 1. Levels of serum slL-2R and clinical severity. Elevation of serum slL-
2R level was observed in nasal allergy patients (n 26) compared with
normal subjects (n 8, **p < 0.01), although there was no significant
correlationbetween serum slL-2R level and clinical severity.
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FIG. 2. Levels of slL-2R in the nasal secretions and clinical severity. The
slL-2R level of the nasal secretions was elevated in the nasal allergy
patients (n 26) compared with the normal subjects (n 9) (*p < 0.05).
There was no significant correlation between slL-2R concentration in the
nasal secretions and clinical severity.
detected in the nasal secretions was significantly
higher than that in the serum (p < 0.01).
Presence of CD25 cells: CD25 cells were found in
the nasal mucosa from the inferior turbinate of nasal
allergy patients (Fig. 3).
Discussion
Interleukin-2 (IL-2) is a T cell growth factor and
plays a central role in the regulation of immune
responses. IL-2 is released from T cells activated by
IL-1 and antigen or mitogen. Cells responsive to IL-
2 include T cells, B cells, natural killer cells and
macrophages/monocytes. Recent studies have
shown that IL-2R has three subunits, an 0t chain, a
chain, and a y chain7. The 0t chain has a low
affinity, while the combination of the 1 and y chains
shows a moderate affinity for IL-2. These three sub-
mits combine to form a high affinity IL-2R, and
binding of IL-2 to IL-2R expressed on the cell mem-
brane induces cellular activation, differentiation and
proliferation. Intracellular signalling through IL-2R is
FIG. 3. Immunostaining of the nasal mucosa obtained from the inferior
turbinate of a nasal allergy patient for CD25 (IL-2R). CD25 cells formed a
cluster in superficial lamina propria. (Original magnification x 185.)
mediated via the associated and y subunits. The sIL-
2R is found in the T cell culture medium containing
a mitogen, and in the serum of patients suffering
from diseases such as adult T cell leukaemia,
Kawasaki disease,
1 rheumatoid arthritis,
11 and bron-
chial asthma. 12 In general, T cells are activated
through the IL-2/IL-2R system and slL-2R may inhibit
the response of the IL-2-sensitive cells to IL-2.11
However, the role of slL-2R in vivo still remains
unclear.
In the present study, we demonstrated elevation of
slL-2R concentrations in both serum and nasal secre-
tions, and observed infiltration of CD25 cells in the
nasal mucosa of nasal allergy patients immunocyto-
chemically. Since CD25 cells are not confined only
to T cells but also include B cells, natural killer cells
and macrophages/monocytes, slL-2R may originate
from all these cells. Thus, further studies are required
to determine the cellular origin of slL-2R in nasal
allergy.
Regarding the origin of slL-2R, an
immunohistological study of the allergic nasal
mucosa after exposure to allergens demonstrated a
significant increase in the number of CD25 (IL-2R-
positive) cells and CD4 helper T cells, and showed
a significant correlation between CD4 and CD25
cells but not between macrophages and CD25 cells.
There were no changes in distribution of CD45 cells,
CD3 cells or CD8 cells in the nasal mucosa. A
significant increase in the ratio of CD4//CD8
lymphocytes was observed in nasal biopsies but not
in the peripheral blood after allergen challenge. 13
These data strongly suggest that slL-2R in the nasal
secretion originates from helper T cells in the nasal
mucosa.
Eosinophils are the major effector cells in the late
response of allergic inflammation causing nonspe-
cifi hyperresponsiveness of the mucosa manifested
by sustained clinical symptoms of nasal allergy. In
the present study, we failed to find a correlation
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between serum levels of sIL-2R and peripheral blood
eosinophil count, or between the levels of slL-2R in
the nasal secretions and graded eosinophilia in nasal
smears. However, a significant correlation was found
between serum slL-2R and blood eosinophil count in
asthmatic patients.
12 Furthermore, it has also been
reported that rlL-2 administration as a part of
immunotherapy for a malignant tumour induced
marked eosinophilia. 14,15 These data still suggest a
positive relationship between IL-2 and eosinophil
accumulation.
The mechanism of IL-2 induced eosinophil infiltra-
tion may possibly be explained by IL-5 derived from
activated T cells. 16,17 IL-5 is a potent and specific
eosinophil growth factor,
TM and significantly prolongs
eosinophil survival. 19 IL-5 also enhances the expres-
sion of adhesion molecules on vascular endothelial
cells,
2 and induces chemotaxis21 and activation of
eosinophils.
18 Therefore, CD25 cells stimulated by
IL-2 might induce eosinophil infiltration in the nasal
mucosa in conjunction with IL-5 released from mast
cells following allergen challenge.
In conclusion, we measured slL-2R levels in the
nasal secretions and sera from nasal allergy patients
and healthy control subjects, and found elevated
levels of sIL-2R concentration in both the nasal secre-
tions and sera in the patients with nasal allergy.
Accumulation of CD25 cells was found in the aller-
gic nasal mucosa by immunocytochemical examina-
tion. These results suggest that T cell activation is
induced in nasal allergy, which results in persistent
inflammation f the nose.
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